SARS-CoV-2-IN-15
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
Product Specifications
CAS Number
1580-42-3
UNSPSC
12352005
Hazard Statement
H315, H320, H335
Target
SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sars-cov-2-in-15.html
Purity
99.65
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
Molecular Formula
C14H9ClF3NO2
Molecular Weight
315.67
Precautions
H315, H320, H335
References & Citations
[1] Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
DIRC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Lamin B Receptor Polyclonal Antibody, FITC Conjugated
